Fibroblast activation protein (FAP)-targeted radioligand therapy is safe and effective for treating patients with progressive metastatic tumors, specifically advanced sarcomas, according to research presented at the 2024 ...
Jun 10, 2024
0
0
In a head-to-head study, FAPI PET/CT was found to be more predictive of progressive pulmonary fibrosis in interstitial lung disease (ILD) patients than 18F-FDG PET/CT. With heightened and extensive uptake compared to 18F-FDG, ...
Jun 10, 2024
0
0
New data on prolonged prostate-specific antigen (PSA) progression and adverse events grouped by safety topic of interest from the PSMAfore study underscore the statistically significant and clinically meaningful radiographic ...
Jun 10, 2024
0
0
The presence of beta-amyloid deposits in the brain significantly limits the effectiveness of cognitive training in healthy older adults, according to new research presented at the 2024 Society of Nuclear Medicine and Molecular ...
Jun 10, 2024
0
0
The use of hearing aids can help to slow the metabolic decline that takes place in the brains of adults with mild cognitive impairment, according to research presented at the 2024 Society of Nuclear Medicine and Molecular ...
Jun 10, 2024
0
1
A novel imaging approach—68Ga-DOTATATE PET/CT—can more accurately differentiate residual/recurrent tumors from post-surgery scar tissue in patients with head and neck paragangliomas (HNPGLs) compared to MRI. Providing ...
Jun 10, 2024
0
0
A novel AI approach can accurately detect six different types of cancer on whole-body PET/CT scans, according to research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. By automatically ...
Jun 10, 2024
0
0
A newly developed radiotracer can generate high quality and readily interpretable images of cardiac amyloidosis, a condition referred to as the "Alzheimer's disease of the heart." As the first amyloid-specific and pan-amyloid ...
Jun 10, 2024
0
0
A new PET radiotracer enables same-day imaging of the important gastrointestinal cancer biomarker known as Claudin18.2 (CLDN18.2). Uptake of the radiotracer, 68Ga-NC-BCH, was found to correlate significantly with CLDN18.2 ...
Jun 6, 2024
0
0
Extended prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (177Lu-PSMA) beyond six cycles is an effective and well-tolerated treatment for metastatic castration-resistant prostate cancer patients, ...
Jun 4, 2024
0
0
